ETCHES Study of CereVasc eShunt for Communicating Hydrocephalus Completes Enrollment

January 21, 2026—CereVasc, Inc. announced the completion of enrollment in its ETCHES 1 study of the company’s eShunt system for the treatment of communicating hydrocephalus.

According to CereVasc, ETCHES 1 is a single-center, open-label, single-arm pilot study examining the feasibility, safety, and performance of the eShunt system in adults who develop communicating hydrocephalus caused by increased intracranial pressure after postaneurysmal subarachnoid hemorrhage (SAH) and require permanent cerebrospinal fluid (CSF) diversion after treatment of the hemorrhage.

The eShunt is designed to drain excess CSF from the intracranial subarachnoid space into the venous system. It is an investigational device and has not been approved by FDA or any other regulatory agency for commercial sale, advised CereVasc.

The study evaluated changes in intracranial pressure and assessed device performance and safety outcomes. The patients will continue to be monitored for safety through 24 months of follow-up after the procedure, noted the company.

ETCHES 1 was performed by neurovascular surgeon and Principal Investigator Pedro Lylyk, MD, with his team from Clinica la Sagrada Familia in Buenos Aires, Argentina.

“I have witnessed encouraging outcomes in patients treated for communicating hydrocephalus with the eShunt system and am honored to have led this critical first-in-human evaluation of post-SAH hydrocephalus,” commented Dr. Lylyk in Cerevasc’s press release. “This minimally invasive procedure offers a promising option for patients who would otherwise be treated with a ventriculoperitoneal shunt, a treatment that can be effective but may be associated with a high rate of complications.”